Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in admission to ICU compared with motavizumab (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.68 [0.89, 3.19]
2 studies · 7870 participants
Moderate

Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection

Palivizumab leads to lower admission to ICU compared with placebo (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.5 [0.3, 0.81]
2 studies · 2789 participants
High